Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

3.11USD
2:02pm EST
Change (% chg)

$-0.01 (-0.32%)
Prev Close
$3.12
Open
$3.11
Day's High
$3.22
Day's Low
$3.06
Volume
118,176
Avg. Vol
315,075
52-wk High
$5.24
52-wk Low
$1.91

Summary

Name Age Since Current Position

Laurence Cooper

53 2018 President, Chief Executive Officer, Director

Kevin Lafond

62 2013 Principal Financial Officer, Chief Accounting Officer, Senior Vice President - Finance, Treasurer

David Mauney

50 2017 Interim Chief Operating Officer, Executive Vice President, Chief Business Officer

Lynn Ferrucci

Senior Vice President - Human Resources, Facilities and Administration

Scott Tarriff

58 2018 Non-Executive Lead Independent Director

James Cannon

79 2005 Independent Director

Elan Ezickson

54 Independent Director

Wyche Fowler

77 2005 Independent Director

Douglas Pagan

46 Independent Director

Biographies

Name Description

Laurence Cooper

Dr. Laurence James Neil Cooper, M.D., Ph.D., is President, Chief Executive Officer, Director of the Company. Prior to joining us, Dr. Cooper led the Pediatric Cell Therapy service (formally named the BMT program) as a tenured professor at the University of Texas M.D. Anderson Cancer Center, or MD Anderson, where he had worked since 2006. In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic hematopoietic stem-cell transplantation, referred to as HSCT, at MD Anderson, he ran a laboratory translating immunology into clinical practice. His program had multiple investigator-initiated trials that infuse T cells and NK cells to target malignancies. Dr. Cooper also holds an appointment as a Visiting Scientist at MD Anderson and as Adjunct Professor of Pathology & Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cooper obtained his BA at Kenyon College in Gambier, Ohio and M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland before training in Pediatric Oncology and Bone Marrow Transplantation, or BMT, at the Fred Hutchinson cancer Research Center in Seattle.

Kevin Lafond

Mr. Kevin G. Lafond, CPA., is the Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer of the Company. Mr. Lafond has served as our Vice President Finance, Chief Accounting Officer and Treasurer since June 2013 and is our principal financial and accounting officer. Previously, Mr. Lafond served as the company’s Corporate Controller since he joined us in February 2009 until June 2013. Prior to joining us, Mr. Lafond served as Controller of Helicos Biosciences Corporation, a public life sciences equipment manufacturer not affiliated with Ziopharm, from February 2007 to October 2008. Mr. Lafond holds a bachelor’s degree from Plymouth State University, master’s degrees in both accounting and taxation from Bentley University and is a Certified Public Accountant.

David Mauney

Dr. David M. Mauney, M.D., is the Interim Chief Operating Officer, Executive Vice President, Chief Business Officer of the Company. Dr. Mauney, served as managing director of Harvest Capital Strategies LLC, where he had worked since 2015. From 2000 to 2015, Dr. Mauney served as managing director of De Novo Ventures, a health care investment firm he co-founded. Dr. Mauney holds a B.A. from Duke University and an M.D. from Dartmouth Medical School.

Lynn Ferrucci

Ms. Lynn Ferrucci is the Senior Vice President - Human Resources, Facilities and Administration of the Company. Ms. Ferrucci has over 20 years of experience in strategic and tactical human resource leadership, including extensive knowledge in mergers and acquisitions, organizational development and compensation as well as benefits. She has developed and implemented company-wide initiatives to motivate and retain employees, as well as directed human resource efforts to attract key talent. Prior to joining ZIOPHARM Oncology, Ms. Ferrucci was the senior vice president of human resources at Clinical Data, Inc., a biopharmaceutical company, which completed more than ten mergers/acquisitions during her tenure and was acquired by Forest Laboratories, Inc. Earlier in her career, Ms. Ferrucci worked in human resources within the manufacturing, service and consulting environments. She holds a bachelor’s degree in management from Rhode Island College.

Scott Tarriff

Mr. Scott L. Tarriff is the Non-Executive Lead Independent Director of the Company effective on September 18, 2018. Mr. Tarriff has been one of our directors since September 2015. Mr. Tarriff has served as the President, Chief Executive Officer and as a member of the Board of Directors of Eagle Pharmaceuticals, Inc. since its inception in January 2007. Prior to joining Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par’s Board of Directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the Board of Directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.

James Cannon

Mr. James A. Cannon is an Independent Director of ZIOPHARM Oncology, Inc. He has been one of our directors since our September 2005 acquisition of ZIOPHARM, Inc. and previously served as a director of ZIOPHARM, Inc. since December 2004. Mr. Cannon is currently Vice Chairman, Chief Financial Officer and a member of the board of directors of BBDO Worldwide, an advertising agency. In these capacities, he oversees the financial management of BBDO operations in 77 countries. Mr. Cannon joined BBDO in 1967, was promoted to Chief Financial Officer of the agency in 1984, and was elected to its board of directors one year later. An integral member of the team that formed Omnicom via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Mr. Cannon became Comptroller of the new group (NYSE: OMC) and a member of its board of directors in 1986, a position he held through 2002. In 1987, he was appointed Director of Financial Operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as Executive Vice President and Chief Financial Officer. His return was concurrent with that of Allen Rosenshine who became Chairman and Chief Executive officer of BBDO after heading Omnicom. Mr. Cannon was promoted to Vice Chairman of the agency in 1990. Mr. Cannon is a graduate of Pace University and served in the U.S. Marine Corps.

Elan Ezickson

Mr. Elan Z. Ezickson is an Independent Director of the Company. Mr. Ezickson is the Chief Operating Officer & Head of Corporate Development for Scholar Rock Holding Corporation, a position he has held since August 2014. Prior to Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. Previously, Mr. Ezickson worked at Biogen Inc. in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Mr. Ezickson holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law. Mr. Ezickson is 54 years old. The board believes that Mr. Ezickson’s deep operating and management experience at several leading life science companies, as well as his legal training, qualifies him to serve on the board.

Wyche Fowler

Sen. Wyche Fowler, Jr., J.D., is an Independent Director of ZIOPHARM Oncology, Inc. Mr. Fowler has been one of our directors since our September 2005 acquisition of ZIOPHARM, Inc. and previously served as a director of ZIOPHARM, Inc. since December 2004. Senator Fowler served for 16 years in the United States Congress representing the state of Georgia, from April 1977 to January 1993. In the U.S. Senate he served as assistant floor leader, helping mold a bipartisan consensus for major public policy issues. Senator Fowler was a member of the U.S. Senate Appropriations, Budget, Energy and Agriculture Committees. First elected to the U.S. House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. Following his service in the United States Congress, Senator Fowler served as U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, The Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the U.S. military in Saudi Arabia. Sen. Fowler was named Lion of Judah by the State of Israel for successfully freeing Soviet Jew Yakov Gluzman. Senator Fowler is currently engaged in an international business and law practice, and serves as Chairman Emeritus of the Board of the Middle East Institute, a non-profit foundation in Washington, D.C. Senator Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust. Senator Fowler holds an A.B. in English from Davidson College and a J.D. from Emory University School of Law.

Douglas Pagan

Mr. Douglas W. Pagan is an Independent Director of the Company. Mr. Pagan is currently serves as Chief Financial Officer of Paratek Pharmaceuticals, Inc., a position he has held since December 2014, where he is responsible for fundraising, financial reporting, investor relations, and strategic planning. Prior to that, Mr. Pagán served as Vice President, Finance at Acceleron Pharma Inc., which he joined in 2008. There, he was responsible for strategic and financial planning, accounting, SEC reporting, treasury and financial operations, including undertaking a significant role in the company’s initial public offering. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson & Johnson. Mr. Pagán received his B.S.E. in Chemical Engineering from Princeton University and his M.B.A. from Columbia Business School. Mr. Pagán is 46 years old. The board believes that Mr. Pagán’s experience as a financial executive in life science and pharmaceutical companies, as well as his prior investment banking experience, will allow Mr. Pagan to provide financial and strategic guidance to the Company and qualifies him to serve on the board.

Basic Compensation

Name Fiscal Year Total

Laurence Cooper

2,594,240

Kevin Lafond

581,224

David Mauney

2,297,970

Lynn Ferrucci

--

Scott Tarriff

128,178

James Cannon

129,448

Elan Ezickson

--

Wyche Fowler

125,448

Douglas Pagan

--
As Of  30 Dec 2017